Skip to main content
    L

    LENZ Therapeutics Inc (LENZ)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.82
    -0.31 (-7.51%)

    Market Cap: $129.77M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    LENZ Therapeutics Inc (LENZ) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to LENZ Therapeutics are Zentalis Pharmaceuticals Llc (ZNTL), NRX Pharmaceuticals (NRXP) and Minerva Neurosciences (NERV). By market cap, LENZ Therapeutics ranks 6th of the 13 companies on this page; Bright Minds Biosciences (DRUG) is the largest at $227.96M.

    Peer Comparison

    LENZ's revenue growth of -72.9% is below the peer median of 0.0%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    LENZ Therapeutics (LENZ)$129.77MN/A9.7x0.0%N/A-72.9%0.00%
    Zentalis Pharmaceuticals Llc (ZNTL)$167.05MN/AN/A0.0%N/A0.0%0.00%
    NRX Pharmaceuticals Inc (NRXP)$95.58MN/A23.8x0.0%N/A0.0%0.00%
    Minerva Neurosciences Inc (NERV)$114.62MN/AN/A0.0%N/A0.0%0.00%
    Tenaya Therapeutics Inc (TNYA)$79.59MN/AN/A0.0%N/A0.0%0.00%
    Sionna Therapeutics, Inc. Common Stock (SION)$150.63MN/AN/A0.0%N/A0.0%0.00%
    NeOnc Technologies Holdings, Inc. Common Stock (NTHI)$141.66MN/AN/A0.0%N/A-100.0%0.00%
    Bright Minds Biosciences Inc (DRUG)$227.96MN/AN/A0.0%-11.2%0.0%0.00%
    Zura Bio Limited Class A Ordinary Shares (ZURA)$119.44MN/AN/A0.0%N/A0.0%0.00%
    Tenax Therapeutics Inc (TENX)$73.77MN/AN/A0.0%N/A0.0%0.00%
    PolyPid (PYPD)$132.25MN/AN/A0.0%N/A0.0%0.00%
    Tiziana Life Sciences Ltd (TLSA)$72.53MN/AN/A0.0%N/A0.0%0.00%
    Rein Therapeutics Inc (RNTX)$47.63MN/AN/A0.0%N/A0.0%0.00%
    Peer median$117.03MN/A23.8x0.0%-11.2%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to LENZ Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Zentalis Pharmaceuticals Llc (ZNTL)
    Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapies for the treatment...
    ZNTL competitors
    NRX Pharmaceuticals Inc (NRXP)
    NRx Pharmaceuticals, Inc., a clinical-stage small molecule pharmaceutical company...
    NRXP competitors
    Minerva Neurosciences Inc (NERV)
    Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of candidate products...
    NERV competitors
    Tenaya Therapeutics Inc (TNYA)
    Tenaya Therapeutics Inc. is a pioneering clinical-stage biotechnology firm that is revolutionizing the treatment of heart disease through its proprietary...
    TNYA competitors
    Sionna Therapeutics, Inc. Common Stock (SION)
    Sionna Therapeutics, Inc. is an innovative biotechnology company focused on developing advanced therapies for neurodegenerative disorders...
    SION competitors
    NeOnc Technologies Holdings, Inc. Common Stock (NTHI)
    NeOnc Technologies Holdings, Inc. is a pioneering biotechnology firm dedicated to revolutionizing cancer treatment through its advanced immunotherapy...
    NTHI competitors
    Bright Minds Biosciences Inc (DRUG)
    Bright Minds Biosciences Inc. (DRUG) is a forward-thinking clinical-stage biotechnology firm specializing in the development of groundbreaking therapies...
    DRUG competitors
    Zura Bio Limited Class A Ordinary Shares (ZURA)
    Zura Bio Limited (Ticker: ZURA) is a biotechnology firm dedicated to developing breakthrough therapies for autoimmune disorders and rare diseases.
    ZURA competitors
    Tenax Therapeutics Inc (TENX)
    Tenax Therapeutics, Inc., a specialty pharmaceutical company, is dedicated to identifying, developing...
    TENX competitors
    PolyPid (PYPD)
    PolyPid Ltd., an advanced stage biopharmaceutical company, develops, manufactures and markets products based on the Polymer Lipid Encapsulation Matrix (PLEX)...
    PYPD competitors
    Tiziana Life Sciences Ltd (TLSA)
    Tiziana Life Sciences Plc, a clinical-stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat...
    Rein Therapeutics Inc (RNTX)
    Rein Therapeutics Inc (RNTX) is a forward-thinking biopharmaceutical company dedicated to developing innovative therapies for neurodegenerative disorders...
    RNTX competitors

    Frequently Asked Questions About LENZ

    Who are LENZ Therapeutics' main competitors?

    The companies most similar to LENZ Therapeutics include Zentalis Pharmaceuticals Llc (ZNTL), NRX Pharmaceuticals (NRXP), Minerva Neurosciences (NERV), Tenaya Therapeutics (TNYA) and Sionna Therapeutics, Inc. Common Stock (SION), listed from the closest match.

    Who is LENZ Therapeutics' biggest competitor?

    Bright Minds Biosciences (DRUG) is the largest of the similar companies at $227.96M; Zentalis Pharmaceuticals Llc (ZNTL) is the closest match by business profile, size, sector and industry.

    How does LENZ stock compare with its competitors?

    LENZ's P/S is 9.7x against a peer median of 23.8x; its net margin is 0.0% against a peer median of 0.0%.

    Which of LENZ Therapeutics' competitors pays a higher dividend?

    LENZ Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is LENZ Therapeutics bigger than its competitors?

    No. LENZ Therapeutics is 6th by market cap among the 13 companies on this page; the largest is Bright Minds Biosciences (DRUG) at $227.96M.